肠促胰素类药物研究与评价征文与优秀病例分析征集通知

发布时间：2018-03-13 23:01

  本文选题：胰高血糖素　切入点：学术合作　出处：《中国医院药学杂志》2016年05期 　论文类型：期刊论文

【摘要】：正自2005年国际上第一个肠促胰素类药的上市以来,此类药物的研究和临床应用有了飞速的发展。目前在我国己经上市的2种胰高血糖素样肽1(GLP-1)受体激动剂和5种二肽基肽酶IV(DPP-4)抑制剂,为了促进肠促胰素类药物在临床应用方面的经验交流,加强学术合作,《中国医院药学杂志》与阿斯利康(中国)联合向全国药学
[Abstract]:Since 2005, when the first enteropancreatins were launched in the world, The research and clinical application of these drugs have developed rapidly. Two glucagon-like peptide (GLP-1) receptor agonists and five dipeptidyl peptidase (IVP) -DPP-4) inhibitors have been listed in China. In order to promote the exchange of experience in clinical application of enteropancreatins and strengthen academic cooperation, the Chinese Journal of Hospital Pharmacy and AstraZeneca (China) have joined hands with AstraZeneca (China) in the field of pharmacology throughout the country.
【作者单位】： 肠促胰素类药物研究与评价征文与优秀病例分析征集组委会;
【分类号】：+
，

本文编号：1608509